【摘要】 遗传性易栓症是指由于患者机体内存在某种基因缺陷而导致抗凝蛋白、凝血因子、纤溶蛋白等相应的蛋白含量减少或者异常,从而具有高血栓栓塞倾向,这些患者常合并静脉血栓栓塞症,而口服抗凝治疗是该类患者管理的重要一环。相比于传统的维生素K拮抗剂(如华法林)作用于多种凝血因子,非维生素K拮抗剂(如新型口服抗凝剂)则仅抑制某一个凝血因子,由于其具有无需常规监测凝血指标、与食物和药物之间相互作用更少、发生出血等不良事件更少等优点,近年来已被越来越广泛地应用于临床抗凝治疗上。该文对口服抗凝药用于遗传性易栓症致静脉血栓栓塞症患者的抗凝治疗进行综述。更多还原

【Abstract】 Inherited thrombophilias are hereditary conditions caused by certain genetic defects that predispose patients to thrombosis.By affecting the quantity and/or function of anticoagulant protein,coagulation factor,or fibrinolytic protein,inherited thrombophilias can disturb the coagulation system.Patients with inherited thrombophilia are constantly complicated with venous thromboembolism.Oral intake of anticoagulants plays an important role in the management of these patients.Compared with traditional vitamin K antagonists(such as warfarin),which inhibit a series of coagulation factors,non-vitamin K antagonists(new oral anticoagulants) only inhibit a certain coagulation factor.Non-vitamin K antagonists offer advantages over vitamin K antagonists,such as less food-drug interaction,no need for laboratory monitoring of coagulation parameters,lower risk of major bleeding.In recent years,non-vitamin K antagonists have been more and more widely applied in clinical anticoagulation therapy.In this article,research progresses on the usage of oral anticoagulants in patients with venous thromboembolism induced by inherited thrombophilia were reviewed.更多还原